The application of anti-MKI67 antibody-conjugated liposomes in breast cancer represents a research strategy aimed at utilizing MKI67 as a biomarker to enhance targeted therapy. MKI67 is a cell proliferation marker that has been extensively studied for its role in assessing tumor prognosis. By using liposomes conjugated with anti-MKI67 antibodies, it is possible to achieve more efficient drug delivery and precise targeting of cancer cells.
The use of anti-MKI67 antibody conjugated liposomes aims to selectively target rapidly proliferating melanoma cells. MKI67 is a well-known proliferation marker, and liposome conjugation allows for enhanced drug delivery to these active tumor cells. This targeted approach could significantly increase therapeutic efficacy while limiting impact on normal, non-dividing cells.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-2237 | Hi-Affi™ Recombinant Rabbit Anti-MKI67 Monoclonal Antibody (DS2237AB) | ELISA, WB, IHC | IgG |
MOR-4638 | Hi-Affi™ Recombinant Rabbit Anti-MKI67 Monoclonal Antibody (TH151DS) | IF, ICC, FC, ChIP | IgG |
MOR-0054-FY | Rabbit Anti-MKI67 Recombinant Antibody (clone AFY0025) | ICC, IHC-P, WB | Rabbit IgG |
There are currently no Customer reviews or questions for VS-1024-FY65. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.